Amidst a national epidemic of opioid abuse, and suicides the need for new therapeutics has gained greater urgency. In it’s first step to meet this urgent need, the FDA took action with the approval of JNJ’s Esketamine in 2019.
George Goldsmith Compass Pathways (CMPS) CEO VIDEO
$CMPS, #CMPS
